USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $-0.97 | $-0.91 | $-0.68 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $10.00M | - | $0.00 |
Forma Therapeutics's next earnings date is Monday, Mar 28, 2022 for the fiscal quarter ending Dec 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $-0.97 | $-1.09 | $-0.92 |
| Mar 2022 | 3 | $-0.93 | $-1.00 | $-0.85 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 7 | $-3.44 | $-3.68 | $-2.65 |
| Dec 2022 | 7 | $-3.85 | $-5.12 | $-2.78 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 3 / 1 | $-0.99 | $-0.99 | $-0.75 |
| Mar 2022 | 1 / 0 | $-0.95 | $-0.95 | $-0.80 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 3 / 0 | $-3.49 | $-3.49 | $-3.19 |
| Dec 2022 | 4 / 0 | $-3.97 | $-3.97 | $-3.71 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $10.00M | $0.00 | $50.00M |
| Mar 2022 | 2 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 5 | $10.00M | $0.00 | $50.00M |
| Dec 2022 | 6 | $2.67M | $0.00 | $8.50M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 12, 2021 | Sep 2021 | $-0.96 | $-0.91 | 5.35% |
| Aug 13, 2021 | Jun 2021 | $-0.79 | $-0.92 | -16.03% |
| May 14, 2021 | Mar 2021 | $-0.76 | $-0.76 | -0.66% |
| Mar 30, 2021 | Dec 2020 | $-0.80 | $-0.68 | 15.00% |
| Nov 12, 2020 | Sep 2020 | $-0.68 | $-0.67 | 1.11% |
| Aug 13, 2020 | Jun 2020 | $-0.95 | $-0.66 | 30.48% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $-3.64 | $-2.01 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 12, 2021 | Sep 2021 | $0.00 | - | - |
| Aug 13, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 14, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $200.00K | $0.00 | - |
| Nov 12, 2020 | Sep 2020 | $500.00K | $0.00 | - |
| Aug 13, 2020 | Jun 2020 | $500.00K | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $170.00K | $0.00 | - |
FMTX's next earnings date is Monday, Mar 28, 2022 for the fiscal quarter ending Dec 31, 2021.
According to 6 analysts, the average EPS estimation for Forma Therapeutics's next quarterly earnings is $-0.97, with a low EPS estimation of $-1.09, and a high estimation of $-0.92.
Over the last 1 month, EPS estimates have seen 3 upward revisions and 1 downward. The EPS 1 month trend is $-0.99, the last 2 month trend is $-0.99, and the 3 month trend is $-0.75.
Based on 5 analysts, the average revenue estimation is $10.00M, with a low revenue estimation of $0.00, and a high estimation of $50.00M.
Forma Therapeutics's previous earnings date was Nov 12, 2021 for its fiscal quarter ended Sep 30, 2021.
FMTX's earnings per share (EPS) was $-0.91, beating the consensus analysts forecast of $-0.96 by 5.35%.
The EPS was higher than the previous fiscal quarter (Jun 2021) by -1.09%, and lower than the same period a year before (Sep 2020) by 35.82%.
The company reported a net income of $-43.29M.Forma Therapeutics's previous annual earnings date was Mar 30, 2021 for its fiscal year ended Dec 31, 2020.
FMTX's earnings per share (EPS) was $-2.01.
Revenues were $0.00.
The company reported a net income of $-70.41M.
Forma Therapeutics reported a free cash flow of $-95.67M for its fiscal year, compared to $-35.02M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
